Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

SOPHiA GENETICS Introduces Innovative Residual Acute Myeloid (RAM) Application

NextEdge Admin

24 Jun 2024

2 min 16 sec

SOPHiA GENETICS a leading healthcare technology company specializing in data-driven medicine, has unveiled its new Residual Acute Myeloid (RAM) Application, enhancing their oncology portfolio to address measurable residual disease (MRD) in global healthcare settings starting this summer.

Acute Myeloid Leukemia (AML) is a significant cancer type, despite its rarity, often relapsing within three years post-remission for over half of patients. Effective post-treatment monitoring is crucial, particularly within the initial two years, to promptly detect relapse. MRD solutions are pivotal in guiding post-remission therapies, detecting early relapses, and serving as a critical endpoint in clinical trials, enhancing patient outcomes.

Philippe Menu, M.D., PhD., Chief Medical Officer and Chief Product Officer at SOPHiA GENETICS, emphasized the importance of MRD in optimizing therapy sequencing and improving AML outcomes. The SOPHiA DDM™ RAM Solution leverages next-generation sequencing (NGS) to achieve high sensitivity, detecting one cancer cell among 10,000 cells. It enables sensitive variant detection down to 0.01% VAF, covering essential genes recommended by guidelines.

Key features include longitudinal variant monitoring, offering insights into mutational changes over time for personalized patient management. The solution integrates updated databases and customizable reporting tools for comprehensive MRD assessments. Moreover, SOPHiA GENETICS plans to refine its machine learning algorithms continuously, promising accurate MRD results within four days.

SOPHiA GENETICS representatives are available at AMP Europe ,June 24-27 to discuss AML monitoring with this new application.